Stay updated on Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page.

Latest updates to the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page
- ChecktodayChange DetectedThe ClinicalTrials.gov footer now displays revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check7 days agoChange DetectedA notice announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs.SummaryDifference1%

- Check14 days agoChange DetectedThe ClinicalTrials.gov footer revision changes from v3.7.1 to v3.7.2 while the page continues to display a 403 error.SummaryDifference0.2%

- Check21 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check35 days agoChange DetectedThe EV-302 study record page now renders a 403 Forbidden error, replacing the usual study content with a minimal error screen. The page shows a Home button instead of the detailed study information.SummaryDifference17%

- Check42 days agoChange DetectedRevision tag updated from v3.6.6 to v3.7.0, indicating a minor update to the page metadata.SummaryDifference0.0%

Stay in the know with updates to Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page.